Ophthalmic Compounding Pharmacies Market By Product Type (Ophthalmic Drops, Ophthalmic Ointments, Ophthalmic Gels, Ophthalmic Suspensions), By Application (Glaucoma Treatment, Dry Eye Syndrome, Cataract Treatment, Retinal Diseases, Corneal Disorders), By End-User (Hospitals, Clinics, Homecare), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Ophthalmic Compounding Pharmacies Market was valued at USD 12.5 billion in 2024-e and will surpass USD 20.4 billion by 2030; growing at a CAGR of 7.3% during 2025 - 2030.

The ophthalmic compounding pharmacies market is growing rapidly due to an increasing prevalence of eye diseases, such as glaucoma, dry eye syndrome, and cataracts. These pharmacies specialize in creating personalized eye care treatments tailored to meet individual patient needs, particularly when commercially available medications are unsuitable. The market is primarily driven by the demand for customized ophthalmic medications, including eye drops, ointments, gels, and suspensions, which are designed to offer effective and targeted treatment for various eye conditions.

Hospitals are the largest end-user segment, as they handle a significant volume of patients requiring specialized eye care. Additionally, the North American region dominates the market due to its advanced healthcare infrastructure, high incidence of eye diseases, and the adoption of personalized treatments. The growing aging population and increasing awareness of eye health contribute to the sustained demand for compounded ophthalmic solutions. As the market evolves, advancements in compounding technology and a focus on precision medicine are expected to further drive growth. Leading companies in the market are emphasizing innovation and regulatory compliance to maintain a competitive edge.

Ophthalmic Drops Segment Is Largest Owing to High Demand in Eye Treatment

The ophthalmic compounding pharmacies market is experiencing significant growth, largely driven by the increasing prevalence of eye diseases and the demand for personalized treatments. As one of the most critical components in the market, ophthalmic drops have emerged as the largest product segment, capturing a significant market share. These drops are commonly used for various eye conditions, such as glaucoma, dry eye syndrome, and infections, providing effective and direct delivery of medication to the affected areas. The ease of use, affordability, and high patient compliance make ophthalmic drops a preferred choice among both healthcare professionals and patients.

Ophthalmic drops are also increasingly being compounded to provide tailored solutions for patients who require specific treatment formulations. This customization is particularly important for patients with unique needs or those who do not respond well to commercially available products. As the demand for personalized medications rises, ophthalmic drops are positioned to continue dominating the market. The growing adoption of eye care solutions that offer more precise dosing and enhanced efficacy is expected to further boost the segment's growth in the coming years.

Glaucoma Treatment Application Is Largest Owing to Prevalence of Eye Diseases

Among the various applications in the ophthalmic compounding pharmacies market, glaucoma treatment is the largest segment, driven by the high global prevalence of glaucoma. Glaucoma is one of the leading causes of blindness worldwide, and its management often requires personalized treatment options. As a result, compounded ophthalmic medications, particularly eye drops, play a crucial role in offering tailored solutions for glaucoma patients. Customized treatments enable healthcare providers to adjust drug dosages and combinations, addressing the specific needs of individual patients.

The growing awareness about glaucoma and the need for early diagnosis and treatment have contributed to the segment's dominance. With advancements in compounding technology and an increasing focus on precision medicine, the glaucoma treatment segment is poised for continued growth. As the global population ages and the incidence of glaucoma rises, the demand for more effective and personalized glaucoma therapies will further drive the market for compounded ophthalmic treatments.

Hospitals Segment Is Largest Owing to High Patient Volume

The end-user segment of the ophthalmic compounding pharmacies market is dominated by hospitals, which account for the largest share. Hospitals are typically the primary healthcare setting where patients receive specialized eye treatments, particularly for conditions like glaucoma, cataracts, and retinal diseases. The high volume of patients seeking treatment for these conditions and the need for personalized medication formulations contribute to the dominance of hospitals in the market. Additionally, hospitals often have the infrastructure and resources to support the compounding of ophthalmic medications on-site, further enhancing their role in the market.

With hospitals being the focal point for surgical procedures and in-patient care for eye diseases, the demand for compounded ophthalmic treatments will continue to rise. Hospitals are increasingly turning to compounding pharmacies to provide customized drug formulations that meet the unique needs of their patients. This trend, combined with advancements in compounding technology, is expected to keep the hospital segment at the forefront of the ophthalmic compounding pharmacies market.

North America Region Is Largest Owing to Advanced Healthcare Systems

In terms of regional dominance, North America is the largest market for ophthalmic compounding pharmacies, owing to its advanced healthcare infrastructure, high prevalence of eye diseases, and strong demand for personalized medications. The region’s well-established healthcare systems, particularly in the United States, offer a conducive environment for the adoption of compounded ophthalmic treatments. Furthermore, regulatory frameworks in North America support the growth of the compounding pharmacy industry, ensuring safety and efficacy in the preparation of ophthalmic medications.

North America’s dominance is also driven by the increasing incidence of eye conditions such as glaucoma and dry eye syndrome, which require specialized treatment. The aging population in this region, combined with a rising focus on personalized healthcare, contributes to the sustained demand for compounded ophthalmic drugs. As healthcare providers in North America continue to emphasize patient-specific therapies, the region is expected to maintain its leadership in the ophthalmic compounding pharmacies market for the foreseeable future.

Leading Companies and Competitive Landscape

The ophthalmic compounding pharmacies market is highly fragmented, with several key players dominating the industry. Leading companies in this market include Fagron, Medisca, Wedgewood Pharmacy, PCCA, and Omnicare, among others. These companies are focusing on expanding their product portfolios, investing in advanced compounding technologies, and forming strategic partnerships to drive growth. Additionally, regulatory compliance and maintaining high standards of patient safety are crucial for these companies to stay competitive in the market.

The competitive landscape is also characterized by innovation, with companies continuously developing new ophthalmic compounding solutions to meet the growing demand for customized treatments. As the market for personalized eye care solutions expands, these leading companies are expected to remain at the forefront by leveraging technological advancements and strengthening their distribution networks. Furthermore, mergers and acquisitions are likely to play a significant role in consolidating the market and expanding the reach of key players across various regions.

Recent Developments:

• Fagron launched a new line of ophthalmic compounds focused on improving the effectiveness of glaucoma treatment, expanding its portfolio of eye care medications.
• Medisca received FDA approval for a new ophthalmic compounding formulation, enabling more precise treatment for patients with retinal diseases.
• PCCA entered into a strategic partnership with a leading hospital network to provide compounded medications for patients undergoing cataract surgeries, enhancing their ophthalmic offerings.
• Omnicare acquired a regional compounding pharmacy to expand its ophthalmic product offerings and improve accessibility to personalized eye care solutions.
• Wedgewood Pharmacy announced the introduction of a new compounded eye drop formulation for dry eye syndrome, offering a more effective treatment option for patients.

List of Leading Companies:

• Fagron
• Cantor & Nissel
• Pharmalex
• Medisca
• PCCA (Professional Compounding Centers of America)
• Omnicare
• Wedgewood Pharmacy
• Chronic Care Pharmacy
• Diamond Pharmacy Services
• Lloyds Pharmacy
• Accredo Health Group
• Village Pharmacy
• Pharmacy Solutions
• American Regent
• Compounding Pharmacy of America

Report Scope: